First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.

Nowotny, Bettina; Thomas, Dirk; Schwers, Stephan; Wiegmann, Sara; Prange, Wolfgang; Yassen, Ashraf; Boxnick, Stefanie

Nowotny, Bettina; Thomas, Dirk; Schwers, Stephan; Wiegmann, Sara; Prange, Wolfgang; Yassen, Ashraf; Boxnick, Stefanie.

Afiliação

Nowotny B; Bayer AG, Research and Development Pharmaceuticals, Wuppertal, Germany.
Thomas D; Bayer AG, Research and Development Pharmaceuticals, Wuppertal, Germany.
Schwers S; Bayer AG, Research and Development Pharmaceuticals, Wuppertal, Germany.
Wiegmann S; Bayer AG, Research and Development Pharmaceuticals, Wuppertal, Germany.
Prange W; Bayer AG, Research and Development Pharmaceuticals, Wuppertal, Germany.
Yassen A; Bayer AG, Research and Development Pharmaceuticals, Wuppertal, Germany.
Boxnick S; CRS Clinical Research Services Wuppertal GmbH, Wuppertal, Germany.

J Thromb Haemost ; 20(7): 1684-1695, 2022 07.

Article em En | MEDLINE | ID: mdl-35490404

Assuntos

Anticoagulantes; Fator XIa; Anticorpos Monoclonais Humanizados/farmacologia; Anticoagulantes/efeitos adversos; Relação Dose-Resposta a Droga; Método Duplo-Cego; Hemorragia/induzido quimicamente; Hemorragia/tratamento farmacológico; Humanos; Masculino; Tempo de Tromboplastina Parcial

Palavras-chave

antibodies, monoclonal, humanized; drug-related side effects and adverse reactions; factor XI; pharmacokinetics; pharmacology

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fator XIa / Anticoagulantes Tipo de estudo: Clinical_trials Limite: Humans / Male Idioma: En Revista: J Thromb Haemost Assunto da revista: HEMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google